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1. Introduction 
The antibiotic daunomycin (fig.1) and its hydroxyl 
derivative adriamycin are highly active anti-cancer 
compounds that have found considerable clinical use 
[l-4]. Whereas both are potent antileukemic agents, 
adriamycin has an exceptionally broad spectrum of 
activity, particularly against a variety of solid tumours. 
The mechanisms of cytoxic activity of these drugs are 
complex, but it is generally accepted that they largely 
act by inhibiting nucleic acid synthesis via direct 
template binding [5-71. In view of the pronounced 
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Fig.1. The structure of daunomycin (R=H). (Adriamycin has 
R=OH). 
* Part V. Part IV: Neidle, S. and Taylor, G. L. (1977) Bio- 
chim. Biophys. Acta 479,450-459 
** Present address: Molecular Biology Laboratory, Birbeck 
College, London WC1 , England 
348 
cardiotoxicity of these drugs, there has been an exten- 
sive search for analogues possessing comparable neo- 
plastic potency yet with reduced harmful sideeffects 
(see,e.g. [2,4,89]). It has been suggested that the 
cardiotoxicity residues in the quinone part of the 
drug molecules, which could be activated to free 
radicals [lo], or which could act as an inhibitor of 
the structurally-related Qlo coenzymes [ 111. 
The interactions of these drugs with DNA at the 
molecular level are believed to involve: 
(i) Intercalation of the planar daunomycinone 
chromophore in between adjacent base pairs of 
the double helix; 
(ii) An electrostatic/hydrogen bond between the 
protonated daunosamine sugar amino nitrogen 
atom, and a phosphate oxygen atom of the poly- 
nucleotide backbone. 
Various molecular models have been proposed for 
this binding, all of which involve these features 
[2,7,12,13]. 
The solid-state conformation of daunomycin has 
been determined in such environments as: pyridine 
[ 141 and butanol [ 1.51 adducts; the N-bromoacetyl 
derivatives [ 161; and I-hydroxydaunomycin (carmino- 
mycin) [17-l 93. In all cases, the apparently flexible 
sugar-chromophore system adopts similar conforma- 
tions. It has therefore been suggested that this preferred 
conformation is a minimumenergy conformation, 
and that it may also be the biologically active confor- 
mation [7 ,141. It plausibly fits into a DNA-binding 
model with the two functional features of the drug 
most important for this (the chromophore and the 
Elsevier/North-Holland Biomedical Press 
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charged nitrogen atom), being optimally spatially 
arranged with respect to each other. 
2. Methods 
Here we have explored,using semiempirical energy The total potential energy of a particular confor- 
calculations, the flexibility of daunomycin about the mation was calculated by a standard semiempirical 
chromophore-sugar linkages. This technique has also approach, using classical in vacua potentialenergy 
been used to study the effects on this flexibility, of functions [20-231. Bond lengths and angles were 
varying several atomic groupings attached to the drug constrained to their crystallographically-determined 
molecule. values [ 141. All computations were performed on 
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Fig.2. Energy map for daunomycin, the contours are at 1 kcal/mol intervals. 
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the University of London CDC7600 computer. 
In all the calculations, the two torsion angles 
simultaneously varied were C8-C7-07-Cl’ (4(l)) 
and C7-07-Cl’-05’ (G(2)). Both were varied 
between 0” and 360’ in 10” intervals, and potential 
energy surfaces were constructed. Relative popula- 
tions of conformers were calculated by a standard 
Boltzmann distribution approach, Differences in con- 
former geometry were defined by a ‘structural 
triangle’ of the three atoms 011,012 and N [24]. 
3. Results and discussion 
Figure 2 shows the energy surface obtained for 
daunomycin itself. There is only one lowenergy 
region which is relatively sharp and well-defined. The 
conformation corresponding to the minimum energy 
is close to, but not identical with, the experimentally- 
determined ones, as defined by the @(I) and G(2) 
values (table 1). The G(1) values differ the most; it is 
significant that the calculated one is closest to that 
found for the IV-bromoacetyl derivative, which does 
not have the intramolecular 07. . .09 hydrogen bond 
in its crystal structure (in contrast to daunomycin 
itself and carminomycin). Examination of the dauno- 
mycin molecular structure shows that the optimum 
geometry for this hydrogen bond is compatible with a 
4(l) of llO-120’. Our calculations, which have not 
taken this additional interaction into account, show 
that the #( 1) = 124’ conformation is only 0.7 kcal/ 
mol less stable than the minimumenergy conforma- 
tion. Computation of the hydrogen-bond stabilisa- 
tion by standard methods [25] gives an associated 
energy of 1.7 kcal/mol, which more than offsets this 
difference. Molecular model-building shows that the 
@( 1) = 93” and 124’ conformations can both fit into 
a DNA-binding model [7,12,13] - the maximal 
differences in the 011-N distances of 0.1 A are not 
significant. 
Figures 3-5 show energy maps for several hypo- 
thetical daunomycin derivatives with varying sub- 
stitution patterns. Deletion of the 09 hydroxyl group 
(fig.3) does not result in any appreciable shift of the 
global energy minimum (table 1); the subsiduary 
minimum at @( 1) = 300’ is of far too high an energy 
to be populated. Similarly, deletion of the -COCHa 
side chain at C9 produces no significant alteration in 
the position of the energy minimum (tig.4), although 
the low-energy region is now more diffuse than that 
for the native drug. Thus, since the relative disposi- 
tions of the nitrogen atom and the chromophore (as 
judged by the 011-N and 012-N distances), remain 
unaltered on going from daunomycin to both these 
putative derivatives, it may be concluded that their 
extent of DNA binding will be closely similar. 
Deletion of the 06 hydroxyl group on the chromo- 
phore ring B results in a rather different situation 
(fig.5). The global minimum remains in the same area 
as before, with a calculated energy of -2.74 kcal/mol; 
however there is now a significant second minimum 
only 0.6 kcal/mol higher in energy, nearly 90’ away 
Table 1 
Geometric features of the lowenergy conformations of daunomycin and several hypothetical derivatives, compared with 
experimentallydetermined values 
Torsion angles, in a 
40) @(2) 
Distances in A Energy (kcal/mol) 
011-012 011-N 012-N 
Daunomycin minimum energy 
Daunomycm minus 06 
Daunomycin minus 09 
Daunomycin minus 06 and 09 
Daunomycin minus -COCH, 
Daunomycin in the crystal [ 141 
Carminomycin [ 17-191 
N-Bromoacetyldaunomycin [ 161 
93 290 2.58 8.92 10.24 -2.89 
121 204 2.58 7.41 7.41 -2.13 
90 288 2.58 8.91 10.21 -2.74 
84 287 2.58 8.90 10.19 -2.51 
121 203 2.58 7.40 7.48 -1.95 
84 290 2.58 8.89 10.22 -2.33 
92 286 2.58 8.91 10.17 -2.29 
125 292 2.58 9.02 10.29 -2.15 
117 290 2.59 8.98 10.24 -2.25 
102 281 2.59 8.88 10.04 -2.48 
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Fig.3. Energy map for daunomycin without 09. 
in G(2). The barrier to rotation between these two 
conformers is -3 kcal/mol, and the subsiduary one 
has a relative population of 26%. Table 1 shows that 
the two conformers have very distinct geometric 
triangulation parameters. It is thus unsurprising that 
the $(2) = 204’ structure cannot effectively bind to 
DNA with simultaneous involvement of the inter- 
calating chromophore and the amine nitrogen atom, 
as judged by our model-building studies. Deletion of 
both 06 and 09 substituents results in an energy map 
displaying features of both fig.4 5 (table 1). In this 
case, the relative population of the minor conformer 
is 35%. 
A study of the thermodynamics of daunomycin- 
DNA binding has shown [26] that the freeenergy 
change on binding is w-8.5 kcal/mol, with an enthalpy 
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Fig.4. Energy map for daunomycin without the -COCH, side chain. 
change of -5.3 kcal/mol. Thus, the barrier to rota- this by deletion of 06 would result in a therapeutically- 
tion of the two (daunomycin minus 06) conformers improved derivative. Our results suggest hat such an 
is low by comparison and one would then not expect approach to a superior drug would be fruitful if 
such a derivative to bind to DNA significantly less simultaneous retention of DNA aflinity is sought. We 
effectively than the parent drug. In view of the thus conclude that none of the structural alterations 
dihydroxyquinoid character of the daunomycinone of daunomycin investigated here will significantly 
chromophore being implicated in its cardiotoxic affect its DNA binding capacity. However, since the 
properties, it might be considered that amendment of biological activity of these drugs is an expression of 
300 
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Fig.5. Energy map for daunomycin without 06.. 
many factors in addition to the purely conforma- 
tional factors outlined above, the possession of pro- 
nounced DNA affinity does not necessarily impart 
useful activity. 
Sanderson and W. A. Thomas for useful discussions. 
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